MSD grabs Eyebiotech Ltd for US$1.3bn upfront
US pharma giant Merck Sharp & Dohme (MSD) is decided to acquire London-based ophtalmology expert Eyebiotech Ltd for upt to US$3bn., US$1.7bn in future milestones.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2153 entries already.
Entries by Thomas Gabrielczyk
SLAS Europe 2024 honours products with most impact
Swiss Seed Biosciences SA and UK-based Cryologyx Ltd have won the SLAS Europe Product Award 2024 for product developments with transformational potential for the sector.
Hornet Therapeutics reports first data of EBV-triggered disease blocker
Hornet Therapeutics Ltd will use a US$5m seed financing to launch clinical tests of its IDO1 blocker HTX-201within the next 12 to 18 months to target post-transplant lymphoproliferative disease.
AstraZeneca puts step into obesity market
Swiss obesity start up SixPeaks Bio AG has made a good start, announcing a US$30m Series A financing led by Versant Ventures and a US$80m biobucks partnership with AstraZeneca plc.
LabGenius raises £35m to expand its antibody discovery platform
London-based AI-driven antibody drug discovery specialist LabGenius Ltd has closed a £35m Series B financing round.
Seed financing for Cellugy A/S
Danish industrial biotechnology startup Cellugy raises €4,9m with the ambition to replace petrochemicals in personal care products.
Obesity: Roche with first clinical data after US$2.7bn deal
Obesity candidate CT-388, which Genentech added to Roche’s pipeline with the acquisition of Carmot Therapeutics, is at least not a disappointment, according to new trial data.
British PrecisionLife Ltd inks partnership with Metrodora Institute
British PrecisionLife Ltd and the Metrodora Institute have announced to launch clinical trials to improve the diagnosis and therapy of long COVID-related ME/CFS.
First dog snack from microbial protein
German-Portuguese biotech start-up MicroHarvest GmbH and a Munich-based pet food manufacturer want to launch the first dog snack made by single cell protein.
AC Immune and Takeda ink US$2.1bn biobucks deal
AC Immune and Takeda have inked an exclusive option license agreement for ACI-24.060, a first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression.